Pieter Muntendam

This inventor holds 11 USPTO granted patents and 21 published patent applications, plus 2 CIPO patents and 11 EPO patents. Top assignees: Scpharmaceuticals Inc., Sq Innovation Ag, Bg Medicine, Inc.. Active years: 2014-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Pieter Muntendam. Retrieved from https://idiyas.com/inventor/pieter-muntendam

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 (Patent Applications = 21)

% Patents Active = 81.8

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 11 (Patent Applications = 13)

Average Co-Inventor Count = 1.5

ph-index = 3

Forward Citations = 40(Granted Patents)

Location History:

Lexington, MA (US) (2018)
Boxford, MA (US) (2014 - 2022)

Company Filing History:

4 out of 14

Scpharmaceuticals Inc.

Years Active: 2014-2026

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12742787 - GALECTIN-3 IMMUNOASSAY (2026-09-22),

2. 12403120 - Pharmaceutical compositions of furosemide and uses thereof (2025-09-02),

3. 12397005 - Pharmaceutical compositions of torsemide and uses thereof (2025-08-26),

4. 12370168 - Pharmaceutical formulations for subcutaneous administration of furosemide (2025-07-29),

5. 12318363 - Pharmaceutical compositions of furosemide and uses thereof (2025-06-03),

6. 11433044 - Pharmaceutical formulations for subcutaneous administration of furosemide (2022-09-06),

7. 11246851 - Pharmaceutical compositions of furosemide and uses thereof (2022-02-15),

8. 10272064 - Pharmaceutical formulations for subcutaneous administration of furosemide (2019-04-30),

9. 9884039 - Pharmaceutical formulations for subcutaneous administration of furosemide (2018-02-06),

10. 9274126 - Risk factors and prediction of myocardial infarction (2016-03-01),

11. 8672857 - Galectin-3 and cardiac resynchronization therapy (2014-03-18),

Title: Innovator Pieter Muntendam: Contributions to Pharmaceutical Science

Introduction

Pieter Muntendam is a distinguished inventor based in Boxford, MA, renowned for his contributions to the field of pharmaceutical sciences. With a portfolio of ten patents, Muntendam has significantly impacted the development of innovative pharmaceutical compositions targeting various health conditions.

Latest Patents

Among his notable patents, two stand out for their relevance to managing serious health issues:

1. **Pharmaceutical Compositions of Furosemide and Uses Thereof**

This patent presents a pharmaceutical composition and a method for administering it to patients suffering from edema, heart failure, kidney, or liver disease. The composition includes furosemide or its pharmaceutically acceptable forms, alongside tris(hydroxymethyl)aminomethane. Notably, it is designed with specific concentrations of furosemide between about 10 mg/mL and 30 mg/mL, while maintaining a pH valued between 8.0 and 8.5 for effective parenteral administration.

2. **Pharmaceutical Compositions of Torsemide and Uses Thereof**

This inventive work encompasses a pharmaceutical composition and an application method to treat similar patient conditions. The composition incorporates torsemide, alongside cyclodextrin, thereby offering a new approach to administering vital medications to those in need.

Career Highlights

Pieter Muntendam's professional journey includes significant tenures at companies such as Scpharmaceuticals Inc. and Sq Innovation Ag. These positions allowed him to explore his inventive capabilities while contributing to advancements in pharmaceutical products.

Collaborations

Through his career, Muntendam has collaborated with esteemed professionals including Scott A Michaels and Glenn R Larsen. These partnerships have fostered a collaborative environment that encourages the integration of ideas and insights leading to innovative solutions.

Conclusion

Pieter Muntendam's work exemplifies the spirit of innovation in the pharmaceutical domain. His patents not only reflect his expertise but also serve as a vital resource for addressing critical health challenges. As his career progresses, Muntendam continues to be a key figure in advancing pharmaceutical technology, influencing the way medications are developed and administered.

Profile summary based on public USPTO records.